CARE: 視覚言語行動推論の高速化を認証するフレームワーク
CARE: Certifying Acceleration for Vision-Language-Action Inference
VLAモデルの高速化手法がタスク成功率を損なうリスクを、ペアロールアウトと統計的保証で評価し、安全に高速化を選定する手法を提案。
詳しい要約
1. どんなもの?
2. 先行研究と比べてどこがすごい?
3. 技術・手法の肝は?
4. どうやって有効だと検証した?
5. 議論はある?
6. 次に読むべき論文は?
※ AIが要旨から生成した要約です。正確性は原文をご確認ください。
著者: Rui Liu, Tong Zheng, Jindong Gu, Zhipeng Wang
分類: cs.CL, cs.LG
原文アブストラクト
While vision-language-action (VLA) models have advanced rapidly, running them at every control step remains expensive. Prior work accelerates VLA inference using techniques like action chunking and visual-token pruning, typically evaluating based on latency and average task success. However, acceleration may discard information and break tasks the original policy would solve, a risk hidden by average metrics. Measuring these failures is challenging because action deviations compound over closed-loop trajectories, meaning task failure is only observable across full episodes. We therefore define an acceleration-induced failure via paired rollouts from identical initial conditions, tracking when the reference succeeds but the accelerated policy fails. To manage this, we introduce CARE, an approach for certified accelerator selection. CARE uses paired rollouts on a calibration set to provide finite-sample guarantees that acceleration-induced failure risk stays below a user-specified budget. It deploys the fastest certified candidate, falling back to the reference if none qualify. By relying only on terminal outcomes and measured compute, CARE applies unchanged across diverse acceleration mechanisms, while sequential testing and failure-triggered reference rollouts keep certification affordable. On four LIBERO suites with OpenVLA-OFT, CARE certifies $9.0$--$10.8\times$ speedups while guaranteeing (at $95\%$ confidence) that at least $85.8\%$ of reference-solved episodes are preserved. Under tight budgets, selectors without guarantees exceed the budget in up to $75\%$ of trials, whereas CARE stays within budget and its sequential form uses $78.9\%$ fewer rollouts than exhaustive evaluation. CARE further generalizes to flow-step reduction for $π_{0.5}$, and to Qwen3.5-9B and Llama-3.1-8B agents in Crafter.